Study on Dexamethasone Treatment for Severe Dengue Infection with Warning Signs

What this Trial Is About

Researchers are evaluating the use of dexamethasone in treating patients with severe dengue infection who show warning signs. This randomized, double-blinded, placebo-controlled trial aims to determine whether steroid therapy may be effective in managing severe dengue, focusing on outcomes such as mortality within 28 days. Participants are randomly assigned to receive either dexamethasone or a placebo. The study uses a parallel design with quadruple masking to ensure unbiased results. Treatments are administered during the febrile phase of dengue infection in patients confirmed by laboratory testing. Throughout the study, participants will be monitored for mortality over 28 days as the primary outcome. Secondary outcomes include the length of hospital stay within the same period. Researchers will carefully track patient responses and safety during the treatment and follow-up phases.

Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)